RxDoctor Payments Data

Felicia Tran, MD

Internal Medicine · Buena Park, CANPI 1225100753

Payments from drug & device makers

$16,882in general payments, 2019–2025

Across 926 payments — averaging $18.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • AstraZeneca$2K
  • Boehringer Ingelheim$2K
  • Novo Nordisk$2K
  • GSK$1K
  • Amgen$1K
  • plus $8K from 43 others

What the payments were for

  • Food & beverage$16,68199%
  • Education$2011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,882 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$35,269
Medicare patients
74
Services billed
587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin74$108,322
JanuviaSitagliptin Phosphate56$76,565
JanumetSitagliptin Phos/Metformin Hcl38$51,392
TrulicityDulaglutide26$41,482
FarxigaDapagliflozin Propanediol28$33,555
ProliaDenosumab19$31,136
Evenity (2 Syringes)Romosozumab-Aqqg13$30,968
OzempicSemaglutide13$17,128
TradjentaLinagliptin13$9,779
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$5,402
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$3,682
Atorvastatin Calcium337$3,205
SynthroidLevothyroxine Sodium15$1,974
Nebivolol Hcl15$1,942
Omega-3 Acid Ethyl Esters15$1,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$839$127,95794 claims
Boehringer IngelheimJardiance, Tradjenta$1,696$118,10087 claims
AmgenProlia, Evenity (2 Syringes)$1,016$62,10432 claims
Lilly USA, LLCTrulicity$1,875$41,48226 claims
AstraZenecaFarxiga$1,767$33,55528 claims
Novo NordiskOzempic$1,687$17,12813 claims
AbbVieSynthroid$906$1,97415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Buena Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →